Cornelius, North Carolina — Balanced Pharma Included (BPI) introduced on Tuesday the acquisition of rights to a promising new non-opioid injectable post-surgical ache aid drug, Enduracaine Dental, for the worldwide dental market.
BPI goals first to seize a share of the $1.4 billion U.S. market potential for multi-day, non-opioid ache aid after knowledge tooth and different dental surgical procedures. Goal enhancements over present merchandise embody three days of analgesia, low toxicity, much less want for opioids, and handy packaging in customary dental cartridges.
Research present that 94% of sufferers presently obtain an opioid prescription following a knowledge tooth extraction and an alarming 14 instances larger threat of opioid abuse following these prescriptions.
Because the U.S. continues to grapple with the continuing opioid epidemic, Balanced Pharma believes including Enduracaine Dental to its improvement pipeline will increase its providing of improved ache administration instruments for dental professionals, and hopes to considerably scale back the variety of opioid prescriptions.
Enduracaine is a patented mixture of tetracaine 0.2%, lidocaine 0.4%, and epinephrine 1:250,000 launched to the surgical market in 2023 as Endura-KT (a compounding package) by Ventis Pharma. Whereas the drug efficiency has been nicely obtained by practitioners in a number of specialties, together with Oral & Maxillofacial Surgical procedure, the package presentation of the product has usability challenges together with a brief shelf-life and the necessity for refrigeration and reconstitution. For dental surgeons, incompatibility with customary dental syringes is an extra barrier to fast adoption.
BPI will use their patented expertise to supply Enduracaine Dental in an ordinary dental cartridge, with a two-year shelf-life and no want for reconstitution or refrigeration.
“If we may give docs a protected, non-opioid drug with three days of analgesia for his or her sufferers, in an ordinary dental cartridge that’s environment friendly for his or her follow, that’s an absolute win,” says BPI CEO Dr. Scott Keadle, a retired dentist.
“We’re happy to associate with Balanced Pharma to make our Enduracaine native anesthetic simpler to make use of for dental surgeons,” says Dr. Lou Stanfield, Chief Scientific Officer at Ventis Pharma. “The Ventis drug delivered within the BPI cartridge is simply what the physician ordered, and we stay up for fast adoption of this new product presentation by our present dental prospects and throughout the dental surgical indication.”
Dr. Keadle provides, “We’re honored to associate with Ventis Pharma and dental professionals to supply sufferers and households the possibility to decrease the danger of ache and opioid related issues after dental surgical procedure.”
Enduracaine Dental and all BPI merchandise are presently in improvement, haven’t but been accredited by the FDA, and are usually not accessible for advertising and marketing or sale in the USA.
BPI intends to make Enduracaine Dental accessible to dental professionals inside the subsequent 12 months.
